MedTrace Logo

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

NCT03245736 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-11-04

Study results available
· View outcomes & findings →

Summary

The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.

Conditions

  • Ovary Cancer
  • Cervix Cancer
  • Endometrium Cancer
  • Bladder Cancer
  • Prostate Cancer
  • Esophagus Cancer
  • Lung Cancer, Nonsmall Cell
  • Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Tisotumab Vedotin

All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).

Sponsors & Collaborators

  • Genmab

    collaborator INDUSTRY

  • Seagen Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Genmab

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-23
Primary Completion
2019-01-10
Completion
2019-01-10
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245736 on ClinicalTrials.gov